Phaseline

Targets › HPX

HPX (Hemopexin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Hematology; next expected readout Oct 2027.

Binds heme and transports it to the liver for breakdown and iron recovery, after which the free hemopexin returns to the circulation. (UniProt, P02790)

Open in Phaseline: the race on HPX, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CSL BehringCSL889
Human hemopexin
HPXPhase 2Sickle Cell Disease Vaso-occlusive CrisisOct 2027

Conditions

Sickle Cell Disease Vaso-occlusive Crisis (1)

Modalities

protein or peptide (1)

Companies

CSL Behring (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.